These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

465 related items for PubMed ID: 21129871

  • 21. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
    Wang YY, Zhang H, Bai H, Wang SH, Wu MN, An TT, Zhao J, Zhuo ML, Duan JC, Wang ZJ, Wang J.
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
    [Abstract] [Full Text] [Related]

  • 22. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
    Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, Burris H, Gatzemeier U, Blatter J, Symanowski JT, Rusthoven JJ.
    J Clin Oncol; 2003 Apr 15; 21(8):1556-61. PubMed ID: 12697881
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [A case of malignant pleural mesothelioma that responded to cisplatin plus pemetrexed rechallenge].
    Shukuya T, Takahashi T, Nakamura Y, Yamamoto N.
    Gan To Kagaku Ryoho; 2010 Mar 15; 37(3):487-90. PubMed ID: 20332689
    [Abstract] [Full Text] [Related]

  • 29. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
    Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A.
    J Clin Oncol; 2006 Mar 20; 24(9):1443-8. PubMed ID: 16549838
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
    Nakagawa K, Yamazaki K, Kunitoh H, Hida T, Gemba K, Shinkai T, Ichinose Y, Adachi S, Nambu Y, Saijo N, Fukuoka M.
    Jpn J Clin Oncol; 2008 May 20; 38(5):339-46. PubMed ID: 18434338
    [Abstract] [Full Text] [Related]

  • 31. Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma.
    Pilling J, Dartnell JA, Lang-Lazdunski L.
    Thorac Cardiovasc Surg; 2010 Jun 20; 58(4):215-9. PubMed ID: 20514576
    [Abstract] [Full Text] [Related]

  • 32. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP, Komar G, Seppänen MP, Dean KI, Minn HR, Kajander SA, Rinta-Kiikka I, Alanen K, Borra RJ, Puolakkainen PA, Nuutila P, Ovaska JT.
    Ann Surg; 2009 Dec 20; 250(6):957-63. PubMed ID: 19687736
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma.
    Hagtvedt T, Seierstad T, Lund KV, Løndalen AM, Bogsrud TV, Smith HJ, Geier OM, Holte H, Aaløkken TM.
    Acta Radiol; 2015 Feb 20; 56(2):152-8. PubMed ID: 24585944
    [Abstract] [Full Text] [Related]

  • 37. Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.
    Marin-Oyaga VA, Salavati A, Houshmand S, Pasha AK, Gharavi M, Saboury B, Basu S, Torigian DA, Alavi A.
    Hell J Nucl Med; 2015 Feb 20; 18(1):11-8. PubMed ID: 25679073
    [Abstract] [Full Text] [Related]

  • 38. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
    Kitajima K, Kuribayashi K, Minami T, Yokoyama H, Nakamura A, Hashimoto M, Kijima T, Hasegawa S, Kaida H, Yamakado K.
    Oncotarget; 2024 Jun 20; 15():408-417. PubMed ID: 38900646
    [Abstract] [Full Text] [Related]

  • 39. Role of 18F-FDG PET for evaluating malignant pleural mesothelioma.
    Nanni C, Castellucci P, Farsad M, Pinto C, Moretti A, Pettinato C, Marengo M, Boschi S, Franchi R, Martoni A, Monetti N, Fanti S.
    Cancer Biother Radiopharm; 2004 Apr 20; 19(2):149-54. PubMed ID: 15186594
    [Abstract] [Full Text] [Related]

  • 40. Prognostic value of pretreatment volume-based quantitative 18F-FDG PET/CT parameters in patients with malignant pleural mesothelioma.
    Kitajima K, Doi H, Kuribayashi K, Hashimoto M, Tsuchitani T, Tanooka M, Fukushima K, Nakano T, Hasegawa S, Hirota S.
    Eur J Radiol; 2017 Jan 20; 86():176-183. PubMed ID: 28027744
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.